69 Best Pharma Startups to Watch in 2024
How do we build this list? TLDR: Using math and experts.
Last update to the database: April 29, 2024. See changelog.
Join 23,000+ founders, operators and investors.
Seedtable Score Learn how we calculate it here
Sign up to Seedtable Intel to access the entire database
company | score | funding | investors | employees | industries | biz model | city | contact |
---|---|---|---|---|---|---|---|---|
Biomedical research discovery tool. |
$60M · Series B | ICONIQ Growth, Index Ventures, Pentech Ventures | 51 to 100 | Health Tech, AI, Biotech, Pharma | B2B, SaaS | London, UK | •••••••••••@causaly.com | |
Portfolio of pharmaceutical research and discovery. |
$33M · Series C | Patient Square Capital, Rock Springs Capital, M&G Investments | 1 to 10 | Biotech, Pharma | London, UK | •••••••••••@apollotherapeutics.com | ||
Developer of therapies for inflammatory and fibrotic diseases. |
$81M · Series A | Sarsia, p53, Forbion Capital Partners | 11 to 50 | Biotech, Pharma | Oslo, Norway | •••••••••••@callunapharma.com | ||
Cancer treatment predictor software. |
$14M · Series A | Hoxton Ventures, Octopus Ventures, Fly Ventures | 11 to 50 | Health Tech, Biotech, Pharma | B2B | London, UK | •••••••••••@pearbio.com | |
ReViral is a biotechnology company that develops and offers antiviral therapies for patients. |
$44M · Series C | Novo A/S, Andera Partners | 11 to 50 | Health Tech, Biotech, Pharma | B2B | London, UK | •••••••••••@reviral.co.uk | |
SafeHeal develops Colovac, an innovative solution for the protection of digestive anastomosis, designed to reduce anastomotic complications. |
$47M | Sofinnova Partners | 1 to 10 | Health Tech, Hardware, Pharma, Manufacturing | B2B | Paris, France | •••••••••••@safeheal.com | |
Patent-protected anti-inflammatory painkiller. |
$6M · Series A | ITV AdVentures | 1 to 10 | Biotech, Pharma | B2C | London, UK | •••••••••••@flarin.co.uk | |
Early detection of Alzheimer's disease (AD) technology. |
$5M · Series A | EIC Accelerator, WA4STEAM, Ship2B | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Barcelona, Spain | •••••••••••@admit-therapeutics.com | |
Producer of gut health binding proteins. |
$32M · Series A | Bill & Melinda Gates Foundation, Novo A/S | 1 to 10 | Biotech, Pharma | B2B | Copenhagen, Denmark | •••••••••••@bactolife.com | |
The Charac app streamlines access to your local pharmacy. Skip the queue, save time and access all of your prescriptions from anywhere. |
$1M · Seed | NPA, MedAdvisor | 1 to 10 | Pharma, Mobile, Ecommerce | B2C, Marketplace | London, UK | •••••••••••@charac.co.uk | |
Cutting-edge immunomodulatory drugs for the treatment of cancer and immune diseases. |
$3M · Series F | The Leukemia & Lymphoma Society’s Therapy Acceleration Program, Omnes Capital, Nestlé Health Science | 51 to 100 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Paris, France | •••••••••••@enterome.com | |
Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases. |
$6M · Series A | Fountain Healthcare Partners | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Paris, France | •••••••••••@ermium.com | |
Treatments for genetic bleeding disorders. |
$135M · Series B | Novo A/S, HealthCap | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Copenhagen, Denmark | •••••••••••@hemab.com | |
Lyphe group is a reliable supplier of medical cannabis care and medicine. |
$6M · Series A | Leafy Tunnel | 51 to 100 | Health Tech, Agritech, Pharma, Manufacturing, Cannabis | B2B | London, UK | •••••••••••@LYPHEGROUP.com | |
Manual provides diagnostic tools and testing to help patients make health-related decisions. |
$6M · Seed | Felix Capital, Cherry Ventures, FJ Labs | 11 to 50 | Health Tech, Fashion, Pharma, Mobile, Ecommerce | B2C | London, UK | •••••••••••@manual.co | |
Myricx Pharma is a drug discovery company focused on developing small molecule inhibitors. |
$6M · Seed | Sofinnova Partners | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma | B2B | London, UK | •••••••••••@myricxpharma.com | |
Qubit Pharmaceuticals is an EIT Health Headstart laureate and is incubated at Paris Biotech Santé. |
$17M · Seed | Quantonation, XAnge | 11 to 50 | Health Tech, Biotech, Pharma, Manufacturing | B2B | Paris, France | •••••••••••@qubit-pharmaceuticals.com | |
We enable healthcare companies to digitize patient interactions and translate data into actionable insights. |
$2M · Seed | Thieme, MassMutual Ventures, MMC Ventures | 11 to 50 | Health Tech, AI, Insuretech, Pharma, Business Intelligence | B2B, SaaS | Vienna, Austria | •••••••••••@xund.ai | |
AI drug discovery platform. |
$16M · Series A | M Ventures | 11 to 50 | Pharma | Paris, France | •••••••••••@iktos.ai | ||
Medicine for rare neurological diseases. |
$59M · Series B | Idinvest Partners, EQT Life Sciences, Droia Ventures | 11 to 50 | Biotech, Pharma | B2C | The Hague, Netherlands | •••••••••••@vicotx.com | |
Cloud-based clinical data platform. |
$6M · Seed | Eight Roads Ventures, Inkef Capital | 101 to 250 | Health Tech, Biotech, Pharma | B2B, SaaS | Amsterdam, Netherlands | •••••••••••@castoredc.com | |
CimCure focuses on design and development of a novel class of active cancer immunotherapies. |
$5M · Seed | Positron Ventures | Health Tech, Biotech, Pharma | B2B | Amsterdam, Netherlands | •••••••••••@cimcure.com | ||
Core Biogenesis is a biotechnology company building next-generation recombinant protein production technologies. |
$3M · Seed | Entrepreneur First, Thia Ventures, XAnge | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma, Manufacturing | B2B | Paris, France | •••••••••••@corebiogenesis.com | |
Immuno-oncology company treats cancer with antibodies. |
$2M · Series A | AlbionVC, Novartis Venture Fund, Epidarex Capital | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma, Manufacturing, Genetics | B2B | London, UK | •••••••••••@epsilogen.com | |
Developer of therapies for treating chronic inflammatory conditions. |
$6M · Seed | Industrifonden, Hadean Ventures | 1 to 10 | Health Tech, Pharma | B2B | Stockholm, Sweden | •••••••••••@gesynta.se | |
HMNC Brain Health is a precision medicine pioneer in psychiatry based in Munich. |
$10M | ALSTIN Capital | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma, Manufacturing | B2B | Munich, Germany | •••••••••••@hmnc-brainhealth.com | |
Data capture for clinical trials. |
$2M · Seed | Bpifrance | 11 to 50 | Health Tech, Pharma, Data and Analytics | B2B, SaaS | Paris, France | •••••••••••@kayentis.com | |
We are a translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered proteins. |
$2M | Hoxton Ventures, Bessemer Venture Partners | 11 to 50 | Health Tech, Biotech, Pharma, Manufacturing | B2B | London, UK | •••••••••••@peptone.io | |
Manufacturer of radio-immunotherapeutic drugs for cancer patients. |
$40M · Series A | Novo A/S, Forbion Capital Partners, BioMedPartners | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma, Manufacturing | B2B | Brussels, Belgium | •••••••••••@precirix.com | |
Manufacturer of oral drugs that specifically inhibit the enzyme cytidine triphosphate synthase 1 (CTPS1). |
$2M · Seed | Bpifrance, Idinvest Partners, AGORANOV | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Paris, France | •••••••••••@step-ph.com | |
Immunotherapy for the treatment of cancer. |
$1M · Seed | Cancer Research Horizons, UK Innovation & Science Seed Fund | 11 to 50 | Biotech, Pharma | B2C | London, UK | •••••••••••@nk-io.com | |
Biotech R&D specializing in miniprotein-based pharmaceuticals and cellular & gene therapy (CGT) products |
$5M · Series A | Széchenyi Capital Fund Management | 11 to 50 | Biotech, Pharma | Budapest, Hungary | •••••••••••@vrgtherapeutics.com | ||
Short-duration psychedelic medicines developer for neuropsychiatric conditions. |
$40M · Series B | Leafy Tunnel, ATAI Life Sciences | 1 to 10 | Biotech, Pharma | B2C | Oxford, UK | •••••••••••@beckleypsytech.com | |
Temperature controlled containers for the pharmaceutical industry. |
$57M · Series C | M&G Investments, MVM Life Science Partners | 101 to 250 | Pharma, Manufacturing | B2B | Zürich, Switzerland | •••••••••••@skycell.ch | |
Early cancer detection diagnostics platform. |
$3M | Inveready | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Madrid, Spain | •••••••••••@amadix.com | |
Therapeutics treatment for strokes and brain injury. |
$2M · Series A | Caixa Capital Risc, Inveready | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Madrid, Spain | •••••••••••@aptatargets.com | |
Biosyntia is a biotech startup within synthetic biology and metabolic engineering. |
$11M · Series B | Sofinnova Partners | 11 to 50 | Health Tech, Biotech, Pharma, Manufacturing | B2B | Copenhagen, Denmark | •••••••••••@biosyntia.com | |
Devon Labs solve patients unmet medical and care needs. |
$4M | Inveready | 1 to 10 | Health Tech, Pharma | B2B | Madrid, Spain | •••••••••••@devonlabs.com | |
Exogene is a biotechnology company accelerating target & TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening. |
$104k · Pre Seed | Atomico, Entrepreneur First | 1 to 10 | Health Tech, AI, Biotech, Deep Tech, Pharma, Data and Analytics | B2B | London, UK | •••••••••••@exogene.co.uk | |
Casein protein manufacturer for animal-free cheese. |
$5M · Seed | Climentum Capital, PUSH Ventures, BackBone Ventures | 1 to 10 | Foodtech, Biotech, Pharma, Manufacturing | B2B | Vienna, Austria | •••••••••••@fermify.org | |
AI-powered data collecting tool for clinical trials. |
$1M · Seed | Kima Ventures, Cathay Innovation, Serena | 11 to 50 | Health Tech, AI, Biotech, Machine Learning, Pharma | B2B, SaaS | Paris, France | •••••••••••@inato.com | |
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. |
$4M · Series A | Unconventional Ventures, The Footprint Firm, Oskare Capital | 1 to 10 | Health Tech, Biotech, Pharma, Manufacturing | B2B | Copenhagen, Denmark | •••••••••••@octarinebio.com | |
Anti-cancer drugs ddevelopers activating protein phosphatase 2A (PP2A) |
$10M · Series A | Novo A/S, Novartis Venture Fund | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Helsinki, Finland | •••••••••••@rappta-therapeutics.com | |
Tuli Health is a digital health platform that provides instant access to private medical appointments and testing. |
$125k · Pre Seed | Y Combinator | 1 to 10 | Health Tech, CPG & Consumer Goods, Pharma | B2B, SaaS | London, UK | •••••••••••@tuli.health | |
XO Life connects patients and pharma for the better life. |
$2M · Seed | Aescuvest | 11 to 50 | Health Tech, Pharma, Sales and Marketing | B2B, Marketplace | Munich, Germany | •••••••••••@xo-life.com | |
Digital pharmacy platform. |
$180k · Seed | Scottish Investment Bank, Par Equity | 51 to 100 | Pharma | B2C, SaaS | London, UK | •••••••••••@wearephlo.com | |
Developer of innovative treatment for muscle wasting disorders. |
$1M · Seed | Mankind Pharma | 1 to 10 | Biotech, Pharma | London, UK | •••••••••••@actimedtherapeutics.com | ||
Testing and certifications platform for any material, product or chemical. |
$2M · Seed | VentureFriends, Lifeline Ventures | 11 to 50 | Biotech, Pharma | Helsinki, Finland | •••••••••••@measurlabs.com | ||
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. |
$29M · Series A | Caixa Capital Risc, Sound Bioventures | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Nantes, France | •••••••••••@aboleris-pharma.com | |
Gene therapy research to tackle genetic diseases. |
$59M · Series A | Gimv | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Zürich, Switzerland | •••••••••••@anjarium.com | |
Cardior Pharmaceuticals discovers and develops medicines and therapeutics for the treatment and prevention of heart disease. |
$76M | BioMedPartners, High-Tech Gründerfonds, Hadean Ventures | 11 to 50 | Health Tech, Biotech, Pharma | B2B | Hanover, Germany | •••••••••••@cardior.de | |
Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need. |
$99M | High-Tech Gründerfonds, Hadean Ventures | 1 to 10 | Health Tech, Biotech, Pharma, Fitness, Manufacturing | B2B | Duisburg, Germany | •••••••••••@emergencetx.com | |
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases. |
$70M | Sofinnova Partners, Novo A/S, Forbion Capital Partners | 251 to 500 | Health Tech, Biotech, Pharma, Genetics | B2B | Manchester, UK | •••••••••••@f2g.com | |
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases. |
$56M · Series B | Balderton Capital, Atomico, Amadeus Capital | 51 to 100 | Health Tech, AI, Biotech, Pharma, Data and Analytics, Business Intelligence | B2B, SaaS | Cambridge, UK | •••••••••••@healx.io | |
ImCheck Therapeutics is a developing novel therapeutics that target members of the butyrophilin (BTN) super-family of checkpoint molecules. |
$102M | Eurazeo, Earlybird Venture Capital, Andera Partners | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Marseille, France | •••••••••••@imchecktherapeutics.com | |
Clinical-stage central nervous system (CNS) technology. |
$110M · Series B | Sofinnova Partners, Forbion Capital Partners, BioMedPartners | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Basel, Switzerland | •••••••••••@noemapharma.com | |
Lab-quality diagnostics for anyone, anywhere, at any time. |
$85M | Oxford Science Enterprises | 51 to 100 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Oxford, UK | •••••••••••@oslerdiagnostics.com | |
Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins. |
$275M | Wellington Management | 251 to 500 | Health Tech, Biotech, Pharma, Robotics, Manufacturing, Genetics | B2B | Oxford, UK | •••••••••••@nanoporetech.com | |
AI-powered CBT therapeutic platform. |
$130k · Pre Seed | Scale Capital, Hadean Ventures, Sweet Studio | 1 to 10 | Health Tech, AI, Pharma, Ecommerce | B2B, Marketplace | Stockholm, Sweden | •••••••••••@alextherapeutics.com | |
Climedo's platform enables cutting-edge clinical validation and product surveillance of medical devices and pharmaceutical products |
$1M · Pre Seed | Nauta Capital | 51 to 100 | Health Tech, Biotech, Pharma, Data and Analytics, Business Intelligence | B2B, SaaS | Munich, Germany | •••••••••••@climedo.de | |
Pre-clinical platform for all kinds of cancer treatment. |
$3M | Investinor | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Oslo, Norway | •••••••••••@hemispherian.com | |
Inossia provides a softener to make bone cements better suited to the mechanical properties of osteoporotic bone. |
$330k · Pre Seed | Almi Invest | 1 to 10 | Health Tech, Hardware, Pharma | B2B | Stockholm, Sweden | •••••••••••@inossia.com | |
MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms. |
$29M | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma, Genetics | B2B | London, UK | •••••••••••@minatx.com | ||
Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's. |
$2M | Sofinnova Partners, Novo A/S, V-Bio Ventures | Health Tech, Biotech, Pharma | B2B | Copenhagen, Denmark | •••••••••••@munatherapeutics.com | ||
Nanoligent aim is the research and development to clinical phases of innovative cancer treatments based on protein nanoparticles. |
$1M · Seed | i&i Biotech Fund | Health Tech, Biotech, Pharma, Robotics, Manufacturing | B2B | Barcelona, Spain | •••••••••••@nanoligent.com | ||
Therapeutic biologics platform to treat metastatic cancer. |
$1M · Seed | Ysios Capital, Asabys Partners | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Barcelona, Spain | •••••••••••@ona-therapeutics.com | |
Pangaea Data provides a machine learning-based software solution making scientific and clinical data more meaningful. |
N/A | Ascension Ventures, Hambro Perks Ltd., IQ Capital Partners | 1 to 10 | Health Tech, AI, Machine Learning, Pharma, Data and Analytics, Business Intelligence | B2B, SaaS | London, UK | •••••••••••@pangaeadata.ai | |
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. |
N/A | Forbion Capital Partners | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma | B2B | London, UK | •••••••••••@pheontx.com | |
Synthace is a Life Sciences R&D cloud platform that enables experiments to be automated, with the resultant data seamlessly integrated. |
N/A | Sofinnova Partners | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma, Manufacturing, Internet of Things | B2B, SaaS | London, UK | •••••••••••@synthace.com |
Sign up to access our full database
Enter your email and get access to 17,000+ technology companies you can partner with – 271 in Pharma.
- Manufacturing... (2505)
- Health Tech... (2416)
- Fintech... (2406)
- Ecommerce... (1781)
- Mobile... (1596)
- AI... (1497)
- Data and Analytics... (1496)
- Business Intell...... (1467)
- Hardware... (1236)
- Climate Tech & ...... (1046)
- Energy & Nuclear... (962)
- Biotech... (947)
- Sales and Marke...... (930)
- Mobility & Tran...... (921)
- Foodtech... (912)
- Proptech & Real...... (893)
- Deep Tech... (807)
- Media and Enter...... (788)
- Crypto & web3... (682)
- Edtech... (651)
- CPG & Consumer ...... (624)
- Privacy and Sec...... (517)
- Developer Tools... (499)
- Gaming... (484)
- Payments... (474)
- Machine Learning... (473)
- Communications... (465)
- Hiring and Recr...... (457)
- Fashion... (425)
- Community & Lif...... (410)
- Agritech... (387)
- Travel Tech... (382)
- Adtech... (369)
- Legal Tech... (350)
- Sportstech... (350)
- Consumer Social... (294)
- Cybersecurity... (284)
- Video... (282)
- Pharma... (272)
- Supply Chain & ...... (270)
- Robotics... (270)
- Creative Tools... (258)
- Productivity Tools... (250)
- Enterprise Soft...... (248)
- Insuretech... (226)
- CRM... (213)
- Future of Work... (210)
- AR / VR... (207)
- Internet of Things... (204)
- Music and Audio... (200)
- Fitness... (190)
- Cloud... (178)
- Service Industry... (161)
- Food Delivery... (134)
- Investing... (130)
- Space Tech... (125)
- Wearables... (112)
- Identity Manage...... (91)
- Navigation and ...... (83)
- Electric Vehicles... (82)
- Publishing... (77)
- ElderTech... (75)
- Personal Finance... (67)
- Messaging... (63)
- Semiconductor... (62)
- Govtech... (62)
- Art... (62)
- Drones... (61)
- Open Source... (55)
- IT Management... (50)
- Pet Tech... (49)
- Quantum Computing... (44)
- FamilyTech & Pa...... (43)
- Esports... (34)
- Genetics... (29)